Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Galera Therapeutics, Inc.GRTX · Entity 15899 | Chief Commercial Officer | March 16, 2023 | March 20, 2023 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Galera Therapeutics, Inc.
Report date March 16, 2023 · Filed March 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,000 |
Reported balance
After 2023-03-16 transaction · row 1
1 source rowRow 1 · 2023-03-16 · Purchase · Acquired 11,000 · Balance 11,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.21 to $2.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.21 to $2.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Lyell Immunopharma, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09 | Direct | 9,250 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:16 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 9,250 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001887762-26-000002 · form4-06122026_080602.xml · derivative · entry 1 Bachleda Mark · CIK 0001887762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2036-06-09 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:48 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 13,000 | $0.00 Strike: $12.47 | $0.00 |
DisclosureSEC source: 0001415889-25-016730 · form4-06112025_090624.xml · derivative · entry 1 Bachleda Mark · CIK 0001887762 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2035-06-08 F1 · derivative.exercise_date: 1/36th of the shares of Common Stock subject to the option shall vest on a monthly basis following the grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Reporting Person remaining in service as a director through the applicable vesting date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | PurchaseCommon Stock | 11,000 | $2.25 | $24,717.00 |
DisclosureSEC source: 0000899243-23-009095 · doc4.xml · nonDerivative · entry 1 Bachleda Mark · CIK 0001887762 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.21 to $2.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 23:56 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-23-006468 · doc4.xml · derivative · entry 1 Bachleda Mark · CIK 0001887762 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-24 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:05 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-22-008580 · doc4.xml · derivative · entry 1 Bachleda Mark · CIK 0001887762 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022. Read SEC document |
| October 08, 2021 Filed Oct 13, 2021 00:23 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-21-039959 · doc4.xml · derivative · entry 1 Bachleda Mark · CIK 0001887762 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-10-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on October 8, 2022, and in thirty-six (36) substantially equal monthly installments over a three year period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.